We use cookies for a better user experience. Click here to know more about it. 


Global Human Growth Hormone Market is Projected to Reach US$ 4.2 Bn by 2023

Author: QYResearch  |   Published Date: 2018-08-17   |   Views: 223


Global Human Growth Hormone Market by Type

Growth hormone (GH), also known as somatotropin (or as human growth hormone in its human form), is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration in humans and other animals. It is thus important in human development. It is a type of mitogen which is specific only to certain kinds of cells. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by somatotropic cells within the lateral wings of the anterior pituitary gland.

There are two types of Human Growth Hormone: Powder and Solvent

Powder type: incidence of antibodies is higher, and the activity is low. Secondary pollution easily

Solvent type: The incidence of antibodies is lower, The activity is high, Nearly no secondary pollution, More stable

Global Human Growth Hormone Market: Market Driver and Restraint

Human Growth Hormone is mainly used in Growth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome,Small for Gestational Age and SHOX Deficiency and others.

GHD may result from a disruption of the GH axis in the hypothalamus or pituitary gland. This etiology of the dysfunction may be congenital or acquired in etiology. The classical presentation of severe GHD is characterized by short stature, slow growth, and delayed skeletal maturation, with reduced secretion of GH in response to provocative stimulation. In spite of this expansive list of etiologies, the cause of GHD in most children is idiopathic. GH treatment of GHD in children is, to a certain extent, standardized worldwide. rhGH is injected once daily by the subcutaneous route, usually in the evening to simulate normal physiology.

Turner syndrome (TS) affects about one in 1500–2500 live-born females. One of the most prevalent and salient features of the syndrome is extremely short stature. Untreated women are approximately 20–21 cm shorter than normal women within their respective populations. rhGH has been used to increase growth and final height in girls who have TS. Although organic GH deficiency is not a feature of TS, the efficacy of rhGH in increasing linear growth and final height in TS patients is well documented.

Children suffering from chronic renal insufficiency are prone to develop severe growth failure. The etiology of uremic growth failure is multifactorial. GH therapy is an accepted measure to increase final height. GH treatment in chronic renal insufficiency has improved final height in various studies. In prepubertal chronic renal insufficiency patients, growth response is positively associated with duration of GH therapy and initial degree of growth failure. It was negatively associated with the duration of dialysis. Doses recommended in children who have chronic renal insufficiency are higher than in patients who have GHD. Among children treated with GH, treatment usually is discontinued after transplantation, but sometimes it is reinstituted if the growth rate remains low. Better outcomes are seen in children who begin treatment earlier, who are younger, and who have milder deterioration in renal function.

Prader–Willi syndrome (PWS) is the first human disorder attributed to genomic imprinting in which genes are expressed differentially based on the parent of origin. Children with PWS demonstrate profoundly abnormal body composition, with a similar phenotype as is seen in classic GHD. Administration of GH to GHD children not only restores linear growth but also promotes growth of lean body mass, decreases fat mass by increasing fat oxidation and total body energy expenditure, increases bone mineral density and improves cardiovascular risk factors. While GH therapy is currently approved for growth failure secondary to PWS, these other benefits alone may justify a trial of GH therapy.

Small for gestational age (SGA) is defined as birth weight or length at least 2 SD score (SDS) below the mean gestational age. Independently of whether these children are born prematurely or at term, most SGA infants experience postnatal growth sufficient to normalize their height by 2 years of age. This is referred to as catch-up growth. Several studies have shown that most of SGA children benefit from GH therapy and attaining a normal adult height.

Global Human Growth Hormone Market: Forecast by Region

North America, Europe, Asia-Pacific, Latin America and Mideast & Africa are the regions that are included in this report. North America is the dominant market in the global Human Growth Hormone market in terms of value. Europe is the second largest market. The Asia-Pacific market is also expected to expand at a fast rate in terms of revenue over the forecast period due to the steadily increasing demand of Human Growth Hormone.

Global Human Growth Hormone Market: Key Players

The major players are Novo Nordisk, Pfizer, Eli Lilly, Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Sandoz International and Anhui Anke Biotechnology

Globally, the Human Growth Hormone industry is concentrated. These manufacturers ranging from large multinational corporations to small privately owned companies compete in this industry. The top six producers account for more than 80% of the revenue market.

Click to view the full report TOC, figure and tables


QYR Clients

  • csl
  • croozer
  • crital alert
  • cristal
  • corveneng
  • coperion
  • contijpi medical
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
More Clients...